United Kingdom

Aurinia Pharmaceuticals Inc (AUPH.OQ)

AUPH.OQ on NASDAQ Stock Exchange Global Market

7:41pm GMT
Change (% chg)

$-0.03 (-0.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)


No Ratios Available.


  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Aurinia Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:

04 Jan 2018

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

11 Dec 2017

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

14 Nov 2017

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

23 Oct 2017

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

20 Oct 2017

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

10 Aug 2017

Earnings vs. Estimates